anti-TCR/anti-B7-H3 bispecific T-cell engager GALDEN platform (Shattuck Labs)

N/A

Report date: 2025/01/26 18:26:31

Base Information

Drug Nameanti-TCR/anti-B7-H3 bispecific T-cell engager GALDEN platform (Shattuck Labs)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionT-cell receptor modulatorsCD276 antigen modulators
TargetsCD276 antigenT-cell receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesShattuck Labs Inc
China Registration ClassN/A

Develop Information

Active CompaniesShattuck Labs Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A